Anixa Biosciences Announces Issuance Of Additional U.S. Patent For Ovarian Cancer Vaccine Technology
Portfolio Pulse from Benzinga Newsdesk
Anixa Biosciences, Inc. (NASDAQ:ANIX) has been granted an additional U.S. patent for its novel ovarian cancer vaccine technology. The patent covers nucleic acid-based delivery of the vaccine, which targets the extracellular domain of anti-Müllerian hormone receptor 2 (AMHR2-ED). Anixa is developing the technology in partnership with Cleveland Clinic and with support from the National Cancer Institute's PREVENT Program.
October 03, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The issuance of an additional patent for Anixa's ovarian cancer vaccine technology broadens its protection and could potentially enhance the company's competitive position in the market.
The additional patent for Anixa's ovarian cancer vaccine technology not only broadens its protection but also potentially enhances its competitive position in the market. This could lead to increased investor confidence and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100